Monthly Archives: February, 2014
IFFGD/DHA Announces Advocacy Day 2014 For Functional GI and Motility Disorders
IFFGD’s grassroots arm, the Digestive Health Alliance, has announced Advocacy Day 2014 which will take place in Washington, DC on June 23-24, 2014. Participants will join IFFGD/DHA staff and functional GI and motility researchers in meeting directly with legislators regarding several issues of concern to the digestive health community. These include HR 842, the bipartisan …
Would Renaming Irritable Bowel Syndrome (IBS) Make a Real Difference?
Over the years, the symptom cluster currently known as irritable bowel syndrome or IBS has been called various other terms that are now outdated. These range from, among others, the extremely vague “nervous stomach” to the inaccurate “spastic colitis,” “irritable colitis,” “mucous colitis” (IBS, as currently understood scientifically, is not a form of colitis.) to “spastic colon,” …
New Research on Biomarkers and MRI Imaging Suggests Directions for Future Diagnosis and Treatment of Irritable Bowel Syndrome (IBS)
January and February 2014 appear to have been good months for IBS research, which may be encouraging to those of us with IBS that scientists around the globe continue to work hard on our behalf. Multiple news reports and newly published study results from separate teams in different countries are intriguing and worthy of mention …
U.S. Food and Drug Administration (FDA) Releases Warning About Sodium Phosphate Laxatives
An announcement from IFFGD recently alerted us to the fact that the U.S. Food and Drug Administration (FDA) recently issued expanded warnings regarding over the counter oral or rectal laxatives that contain sodium phosphate, due to increased risks of severe side effects or death in certain groups of users. Currently, labels state to take a …
IBS IMPACT 